Research progress of HIV-1 drug resistance mutations
WU Shou-li1, 2, 3, LIU Feng3, YAN Ping-ping1, 2, WANG Zheng-hua1, 2, YAN Yan-sheng1, 2, 3
1.Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350001, China; 2.Fujian Provincial Key Laboratory of Zoonosis Research, Fuzhou 350001, China; 3.School of Public Health, Fujian Medical University, Fuzhou 350108, China
Abstract：By the end of 2015, all over the world there were around 17 million HIV/AIDS cases received antiretroviral therapy, the HIV-1 morbidity and mortality decreased rapidly. With antiretroviral treatment to all HIV infected persons, HIV resistance mutation is also a threat to the long-term treatment and also, had a negative impact on the important public health strategy of the global elimination in 2030. This review attempts to proceed from different economic and geographical environment, describing genetic barrier of commonly used antiretroviral drugs, the degree of their cross-reactions, and the epidemiology and management of drug-resistant mutations from the individual and group levels. The paper also summarizes the prevalent modes of transmitted drug resistance (TDR) and acquired drug resistance (ADR) in both high-income and low-and middle-income countries (LMICs), and analyze the two kind problems of public health significance to HIV resistant mutations,i.e. pre-treatment resistance (PDR) and preexposure prophylaxis (PrEP). In addition, in view of effectivel HIV cases of treatment and management in different countries, this paper also analyzes the genotypic resistance testing and treatment practices related to AIDS prevention and control. The content has a certain reference function to our country.
吴守丽, 刘峰, 颜苹苹, 王征桦, 严延生. HIV-1耐药突变的研究进展[J]. 中国人兽共患病学报, 2018, 34(1): 44-53.
WU Shou-li, LIU Feng, YAN Ping-ping, WANG Zheng-hua, YAN Yan-sheng. Research progress of HIV-1 drug resistance mutations. Chinese Journal of Zoonoses, 2018, 34(1): 44-53.
[1] UNAIDS. Fast-Track: Ending the AIDS Epidemic by 2030[EB/OL][2017-10-27]. 2014. Available at:http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf, Geneva, Switzerland. [2] UNAIDS. Fact Sheet 2016[EB/OL][2017-10-27]. Available at: http://www.unaids.org/en/resources/fact-sheet.,Geneva, Switzerland. [3] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach-Second edition[EB/OL][2017-10-27]. Available at: http://www.who.int/hiv/pub/arv/arv-2016/en/. Geneva, Switzerland. [4] Phillips AN, Cambiano V, Miners A, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis[J]. Lancet HIV, 2014, 1(2): e85-93. doi:10.1016/S2352-3018 (14) 70021-9 [5] Gallant JE, Koenig E, Andrade-Villanueva JF, et al. Brief report: Cobicistat compared with ritonavir as a pharmaco enhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results[J]. J Acquir Immune Defic Syndr, 2015, 69(3): 338-340. doi:10.1097/QAI.0000000000000598 [6] Margot NA, Johnson A, Miller MD, et al. Characterization of HIV-1 resistance to tenofovir alafenamide in vitro[J]. Antimicrob Agents Chemother, 2015, 59(10): 5917-5924. doi:10.1128/AAC.01151-15 [7] Waning B, Diedrichsen E, Moon S. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries[J]. J Int AIDS Soc, 2010, 13: 35. doi:10.1186/1758-2652-13-35 [8] Abram ME, Ferris AL, Shao W, et al. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication[J]. J Virol, 2010, 84(19): 9864-9878. doi:10.1128/JVI.00915-10 [9] Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection[J]. Proc Natl Acad Sci U S A, 2008, 105(21): 7552-7557. doi:10.1073/pnas.0802203105 [10] Coffin JM. HIV population dynamics in vivo : implications for genetic variation, pathogenesis, and therapy[J]. Science, 1995, 267(5197): 483-489. doi:10.1126/science.7824947 [11] Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing[J]. Infect Genet Evol, 2016, 46: 292-307. doi:10.1016/j.meegid.2016.08.031 [12] Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing[J]. J Antimicrob Chemother, 2014, 69(1): 12-20. doi:10.1093/jac/dkt316 [13] Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1[J]. Antimicrob Agents Chemother, 2000, 44(4): 920-928. doi:10.1128/AAC.44.4.920-928.2000 [14] Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing[J]. J Antimicrob Chemother, 2014, 69(1): 12-20. doi:10.1093/jac/dkt316 [15] Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates[J]. AIDS, 2002, 16(15): F41-47. [16] Woods CK, Brumme CJ, Liu TF, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool[J]. J Clin Microbiol, 2012, 50(6): 1936-1942. doi:10.1128/JCM.06689-11 [17] Rhee SY, Sankaran K, Varghese V, et al. HIV-1 protease, reverse transcriptase, and integrase variation[J]. J Virol, 2016, 90(13): 6058-6070. doi:10.1128/JVI.00495-16 [18] Keys JR, Zhou S, Anderson JA, et al. Primer ID informs next-generation sequencing platforms and reveals preexisting drug resistance mutations in the HIV-1 reverse transcriptase coding domain[J]. AIDS Res Hum Retroviruses, 2015, 31(6): 658-668. doi:10.1089/AID.2014.0031 [19] Dudley DM, Chin EN, Bimber BN, et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance[J]. PLoS One, 2012, 7(5): e36494. doi:10.1371/ journal.pone.0036494 [20] Lapointe HR, Dong W, Lee GQ, et al. HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument[J]. Antimicrob Agents Chemother, 2015, 59(11): 6824-33. doi:10.1128/AAC.01490-15 [21] Panpradist N, Beck IA, Chung MH, et al. Simplified paper format for detecting HIV drug resistance in clinical specimens by oligonucleotide ligation[J]. PLoS One, 2016, 11(1): e0145962. doi:10.1371 /journal. pone.0145962 [22] Chung MH, Beck IA, Dross S, et al. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya[J]. J Acquir Immune Defic Syndr, 2014, 67(3): 246-253. doi:10.1097/QAI.0000000000000312 [23] Lee GQ, Bangsberg DR, Muzoora C, et al. Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda[J]. AIDS Res Hum Retroviruses, 2014, 30(9): 896-906. doi:10.1089/AID. 2014. 0043 [24] Melikian GL, Rhee SY, Taylor J, et al. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility[J]. Antimicrob Agents Chemother, 2012, 56(5): 2305-2313. doi:10.1128/AAC.05487-11 [25] Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing[J]. J Antimicrob Chemother, 2014, 69(1): 12-20. doi:10.1093/jac/dkt316 [26] Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis[J]. PLoS Med, 2015, 12(6): e1001845. doi:10.1371/journal.pmed.1001845 [27] Wensing AM, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1[J]. Top Antivir Med, 2014, 22(3): 642-650. [28] Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications[J]. Drugs, 2012, 72(9): e1-25. doi:10.2165/11633630-000000000-00000 [29] Skhosana L, Steegen K, Bronze M, et al. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa[J]. PLoS One, 2015, 10(2): e0118145. doi:10.1371/journal.pone.0118145 [30] TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study[J]. Lancet Infect Dis, 2016, 16, 565-575. doi:10.1016/S1473-3099 (15)00536-8 [31] Lanier ER, Ait-Khaled M, Scott J, et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors[J]. Antiviral Therapy, 2004, 9: 37-45. [32] Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients[J]. J Infect Dis, 2004, 189: 837-846. doi:10.1086/381784 [33] Collins SE, Grant PM, Shafer RW. Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients[J]. Drugs, 2016, 76: 75-98. doi:10.1007/s40265-015-0515-6 [34] Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study[J]. J Infect Dis, 2014, 210: 354-362. doi:10.1093/infdis/jiu051 [35] El Bouzidi K, White E, Mbisa JL, et al. Protease mutations emerging on darunavir in protease inhibitor-naive and experienced patients in the UK[J]. J Intl AIDS Society, 2014, 17: 19739. doi:10.7448/IAS.17.4.19739 [36] Lopez-Cortes LF, Castano MA, Lopez-Ruz MA, et al. Effectiveness of litonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens[J]. PLoS One, 2016, 11: e0148924. doi:10.1371/journal.pone.0148924 [37] Sutherland KA, Mbisa JL, Cane PA, et al. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1[J]. J General Virol, 2014, 95: 190-200. doi:10.1099/vir.0.055624-0 [38] Rhee SY, Sankaran K, Varghese V, et al. HIV-1 protease, reverse transcriptase, and integrase variation[J]. J Virol, 2016, 90: 6058-6070. doi:10.1128/JVI.00495-16 [39] Rhee SY, Taylor J, Fessel WJ, et al. HIV-1 protease mutations and protease inhibitor cross-resistance[J]. Antimicrob Agents Chemother, 2010, 54: 4253-4261. doi:10.1128/AAC.00574-10 [40] White KL, Kulkarni R, McColl DJ, et al. Week 144 resistance analysis of elvitegravir/cobicistat/ emtricitabine/t enofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients[J]. Antivir Ther, 2015, 20: 317-327. doi:10.3851/IMP2885 [41] Castagna A, Spagnuolo V, Galli L, et al. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results[J]. AIDS, 2014, 28: 2269-2279. doi:10.1097/QAD.0000000000000407 [42] Tan Q, Zhu Y, Li J, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex[J]. Science, 2013, 341: 1387-1390. doi:10.1126/science.1241475 [43] Jiang X, Feyertag F, Meehan CJ, et al. Characterizing the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor[J]. J Virol, 2015, 89: 11457-11472. doi:10.1128/JVI.01384-15 [44] Archer J, Weber J, Henry K, et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism[J]. PLoS One, 2012, 7: e49602. doi:10.1371/journal.pone.0049602 [45] Kolomeets AN, Varghese V, Lemey P, et al. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses[J]. AIDS, 2014, 28: 1-8. doi:10.1097/QAD.0000000000000485 [46] Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial[J]. J Infect Dis, 2014, 210: 1217-1227. doi:10.1093/infdis/jiu233 [47] Baeten, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women[J]. N Engl J Med, 2012, 367: 399-410. doi:10.1056/NEJMoa1108524 [48] Avila-Rios S, Garcia-Morales C, Tapia-Trejo D, et al. HIV pre-treatment drug resistance in Mexico: A nationally representative WHO durvey. Abstract 64, 2016, XXV International HIV Drug Resistance Workshop, Boston, USA. [49] Li JF, Linley L, Kline R, et al. Sensitive sentinel mutation screening reveals differential underestimation of transmitted HIV drug resistance among demographic groups[J]. AIDS, 2016, 30: 1439-1445. doi:10.1097/ QAD.0000000000001099 [50] Mourad R, Chevennet F, Dunn DT, et al. A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK[J]. AIDS, 2015, 29: 1917-1925. doi:10.1097/QAD.0000000000000768 [51] Castro H, Pillay D, Cane P, et al. Persistence of HIV-1 transmitted drug resistance mutations[J]. J Infect Dis, 2013, 208: 1459-1463. doi:10.1093/infdis/jit345 [52] Schultze A, Phillips AN, Paredes R, et al. HIV resistance testing and detected drug resistance in Europe[J]. AIDS, 2015, 29: 1379-1389. doi:10.1097/QAD.0000000000000708 [53] Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals[J]. Clin Infect Dis, 2014, 58: 1165-1173. doi:10.1093/cid/ciu019 Bonner K, Mezochow A, Roberts T, et al. Viral load monitoring as a tool to reinforce adherence: a systematic review[J]. J Acquired Immune Deficiency Syndromes, 2013, 64: 74-78. doi:10.1097/QAI.0b013e31829f05ac [55] Paton N, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa[J]. N Engl J Med, 2014, 371: 234-247. doi:10.1056/NEJMoa1311274
2018, Vol. 34 
